Table 1

Published datasets included in the meta-analysis
Study
 n
 Median age (years)
 Microarray
 Tumor size
 Lymph nodes (LN)
 Treatment
 Stage/grade
Chin and colleagues [55]
 118
 55.3 (SD = 14.3)
 Affymetrix
 2.6 cm (SD = 1.3)
 67 LN-positive, 51 LN-negative
 60% tamoxifen, 52% adjuvant chemotherapy, 51% radiation
 26 stage 1, 70 stage 2, 14 stage 3, 5 stage 4; 10 grade 1, 42 grade 2, 61 grade 3; 5 unknown
Desmedt and colleagues [56]
 198
 47 (all < 61)
 Affymetrix
 < 5 cm
 Node-negative
T1–T2
Ginestier and colleagues [57]
 55
Affymetrix

19 amplified for 20q13, 36 unamplified for 20q13
 Consecutive cases, unilateral localized invasive breast cancer
Hess and colleagues [58]
 133
 Training set, 52 (range 29 to 79); validation set, 50 (range 28 to 73)
 Affymetrix

Preoperative weekly paclitaxel and fluorouracil–doxorubicin–cyclophosphamide chemotherapy
 Stage I, stage II, stage III
Ivshina and colleagues [59]
 249 (Uppsala cohort)
 62.3
 Affymetrix
 2.9 cm
 35% node-positive
 30.3% endocrine therapy, 10.7% chemotherapy, 1.7% combination therapy, 58.8% no systemic therapy
 68 grade 1, 126 grade 2, 55 grade 3
Miller and colleagues [60]
 251
 62.1 (SD = 13.9)
 Affymetrix
 22.4 mm (SD = 12.5)
 84/253 LN metastasis, 160 node-negative, 9 unknown node status
 143 no adjuvant therapy; others with systemic adjuvant therapy, and/or chemotherapy
Minn and colleagues [61]
 82
 55.8 (SD = 13.5)
 Affymetrix
 3.68 cm (SD = 1.77 cm)
 Average 3.5 (SD = 5.98) axillary LN
 Adjuvant chemotherapy and/or hormonal therapy
Richardson and colleagues [62]
 39
Affymetrix



Saal and colleagues [37]
 105
 61 (range 26 to 77)
 Non-Affymetrix
 27 mm (range 2 to 50 mm)
 65 (62%) LN-positive
 Treated uniformly with 2 years of adjuvant tamoxifen
 Stage II, primary breast cancer
Sotiriou and colleagues [63]
 119 (KJ125 dataset)
 45% < 50, 55% > 50
 Affymetrix
 61% < 2 cm, 39% > 2 cm
 LN-negative
 No adjuvant systemic therapy
 34 grade 1, 46 grade 2, 28 grade 3, 17 not available
Turashvili and colleagues [32]
 10
Affymetrix


3 grade I, 5 grade II, 2 grade III
van de Vijver and colleagues [64]
 295
 < 52
 Non-Affymetrix
 < 5 cm
 151 LN-negative, 144 LN-positive
 Modified radical mastectomy or breast-conserving surgery
 Stage I or stage II breast cancer
Wang and colleagues [65]
 286
 54 (SD = 12)
 Affymetrix
LN-negative
 No adjuvant treatment
Yu and colleagues [38]
 96 (only 68 with Notch-1 and survivin data)
 55 (SD = 10.9)
 Affymetrix
 37.7 mm (SD = 17.9)
 37.5% LN-negative
2 unknown grade, 5 grade I, 26 grade II, 63 grade III
Zhao and colleagues [36]
 59 (35 intraductal carcinoma, 17 intralobular carcinoma; three from each with unknown ER status)
 Ductal, 53 (SD = 15.5); lobular, 63.5 (SD = 14.0)
 Non-Affymetrix
Ductal, 16 LN-positive, 16 LN-negative, 3 LN unknown; lobular, 7 LN-positive, 7 LN-negative, 4 LN unknown
Ductal, 5 grade I, 19 grade II, 11 grade III; lobular, 17 grade II, 1 grade I

Sixteen datasets derived from an unbiased search of human breast cancer microarrays on Oncomine were identified that matched the study criteria.

Lee et al. Breast Cancer Research 2008 10:R97   doi:10.1186/bcr2200

Open Data